Showing 1711 results
-
Press release /Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the…
-
Press release /New analyses from the FLAME study suggest dual bronchodilator Ultibro® Breezhaler® provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil (a type of…
-
Press release /Cosentyx® delivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in the vast majority of patients and continues to show a favorable safety profile over 4 years[1] New data show…
-
Press release /Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced…
-
Ad hoc release /FDA approval for Cosentyx® is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial…
-
Press release /CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) compared to Stelara® at Week 16[1] Cosentyx showed greater improvements…
-
Press release /Heart failure (HF) patients with reduced ejection fraction treated with Entresto experienced significantly less reduction in kidney function compared to patients treated with standard of care ACE…
-
Press release /The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF)Potential Q1 2021 sNDA approval…
-
Press release /Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo1…
-
Press release /NEDA-4 - no evidence of disease activity based on four parameters - relapses, MRI lesions, brain shrinkage and disability progression - is a comprehensive measure of MS disease control 31.2%…